Natco Pharma Ltd. Nine-Monthly Results: Standalone & Consolidated Reports

Nine Monthly Results

Results Snapshot

Figures in Cr

Consolidate Nine Monthly Results

Dec'25

Dec'24

Dec'23

Dec'22

Dec'21

Dec'20

Dec'19

Net Sales

3,339.20

3,208.50

2,930.50

1,809.20

1,348.00

1,720.80

1,460.20

Other Operating Income

0.00

Total Operating income

3,339.20

3,208.50

2,930.50

1,809.20

1,348.00

1,720.80

1,460.20

Raw Material Cost

490.70

367.20

394.90

329.00

326.10

283.60

221.20

Purchase of Finished goods

165.70

125.30

120.30

124.40

26.00

183.60

73.90

(Increase) / Decrease In Stocks

-120.60

-51.90

58.80

-84.50

-87.50

-10.30

-8.40

Employee Cost

528.70

435.10

382.50

367.80

335.50

320.30

293.40

Power Cost

0.00

Manufacturing Expenses

0.00

Selling and Distribution Expenses

0.00

Other Expenses

965.80

684.90

719.90

476.00

465.80

413.60

425.80

Total Expenditure (Excl Depreciation)

2,030.30

1,560.60

1,676.40

1,212.70

1,065.90

1,190.80

1,005.90

Operating Profit (PBDIT) excl Other Income

1,308.90

1,647.90

1,254.10

596.50

282.10

530.00

454.30

Other Income

219.80

288.20

86.10

75.60

85.20

75.20

85.00

Operating Profit (PBDIT)

1,528.70

1,936.10

1,340.20

672.10

367.30

605.20

539.30

Interest

25.80

13.70

13.00

11.80

11.00

9.80

18.00

Exceptional Items

0.00

Gross Profit (PBDT)

1,502.90

1,922.40

1,327.20

660.30

356.30

595.40

521.30

Depreciation

156.20

136.90

131.30

122.80

104.50

86.50

69.30

Profit Before Tax

1,346.70

1,785.50

1,195.90

537.50

251.80

508.90

452.00

Tax

208.10

308.10

193.90

98.00

31.30

119.50

87.10

Provisions and contingencies

0.00

Profit After Tax

1,138.60

1,477.40

1,002.00

439.50

220.50

389.40

364.90

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

1,138.60

1,477.40

1,002.00

439.50

220.50

389.40

364.90

Share in Profit of Associates

10.90

0.00

Minority Interest

0.70

0.20

0.00

-0.10

Other related items

0.00

Consolidated Net Profit

1,150.60

1,478.80

1,002.00

439.50

220.50

387.90

365.00

Equity Capital

35.80

36.50

36.40

Face Value

2.0

Reserves

0.00

Diluted Earnings per share

8.46

7.43

11.88

3.41

4.4

3.43

5.73

Operating Profit Margin (Excl OI)

39.2%

51.36%

42.79%

32.97%

20.93%

30.8%

31.11%

Gross Profit Margin

45.01%

59.92%

45.29%

36.5%

26.43%

34.6%

35.7%

PAT Margin

34.1%

46.05%

34.19%

24.29%

16.36%

22.63%

24.99%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Nine Monthly Analysis Highlights

Net Sales

YoY Growth in nine months ended Dec 2025 is 4.07% vs 9.49% in Dec 2024

Consolidate Net Profit

YoY Growth in nine months ended Dec 2025 is -22.19% vs 47.58% in Dec 2024

Operating Profit (PBDIT) excl Other Income

YoY Growth in nine months ended Dec 2025 is -20.57% vs 31.40% in Dec 2024

Interest

YoY Growth in nine months ended Dec 2025 is 88.32% vs 5.38% in Dec 2024

Operating Profit Margin (Excl OI)

YoY Growth in nine months ended Dec 2025 has fallen from Dec 2024

Compare Nine Monthly Results Of Natco Pharma With

Select Peers

Figures in Cr

Consolidate Nine Monthly Results

Change(INR)

Change(%)

Net Sales

3,339.20

5,497.18

-2,157.98

-39.26%

Other Operating Income

0.00

Total Operating income

3,339.20

5,497.18

-2,157.98

-39.26%

Raw Material Cost

490.70

1,343.14

-852.44

-63.47%

Purchase of Finished goods

165.70

379.09

-213.39

-56.29%

(Increase) / Decrease In Stocks

-120.60

-269.93

149.33

55.32%

Employee Cost

528.70

1,293.02

-764.32

-59.11%

Power Cost

0.00

Manufacturing Expenses

0.00

Selling and Distribution Expenses

0.00

Other Expenses

965.80

1,861.32

-895.52

-48.11%

Total Expenditure (Excl Depreciation)

2,030.30

4,606.64

-2,576.34

-55.93%

Operating Profit (PBDIT) excl Other Income

1,308.90

890.54

418.36

46.98%

Other Income

219.80

28.91

190.89

660.29%

Operating Profit (PBDIT)

1,528.70

919.45

609.25

66.26%

Interest

25.80

71.06

-45.26

-63.69%

Exceptional Items

0.00

-42.23

42.23

100.00%

Gross Profit (PBDT)

1,502.90

806.16

696.74

86.43%

Depreciation

156.20

229.96

-73.76

-32.08%

Profit Before Tax

1,346.70

574.36

772.34

134.47%

Tax

208.10

106.04

102.06

96.25%

Provisions and contingencies

0.00

Profit After Tax

1,138.60

470.16

668.44

142.17%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

1,138.60

470.16

668.44

142.17%

Share in Profit of Associates

10.90

-0.87

11.77

1,352.87%

Minority Interest

0.70

0.73

-0.03

-4.11%

Other related items

0.00

Consolidated Net Profit

1,150.60

472.06

678.54

143.74%

Equity Capital

35.80

39.31

-3.51

-8.93%

Face Value

2.00

0.00

Reserves

0.00

Gross Profit Margin

45.01%

14.66%

0.00

30.35%

PAT Margin

34.10%

8.55%

0.00

25.55%

Public Share Holdings (%)

0.00%

0.00

0.00%

Pledged Promotor Holding (%)

0.00%

0.00

0.00%

Nine Monthly - Net Sales

Net Sales 3,339.20 Cr

in Dec 2025

Figures in Cr

YoY Growth in nine months ended Dec 2025 is 4.07% vs 9.49% in Dec 2024

Nine Monthly - Consolidate Net Profit

Consolidate Net Profit 1,150.60 Cr

in Dec 2025

Figures in Cr

YoY Growth in nine months ended Dec 2025 is -22.19% vs 47.58% in Dec 2024

Nine Monthly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 1,308.90 Cr

in Dec 2025

Figures in Cr

YoY Growth in nine months ended Dec 2025 is -20.57% vs 31.40% in Dec 2024

Nine Monthly - Interest

Interest 25.80 Cr

in Dec 2025

Figures in Cr

YoY Growth in nine months ended Dec 2025 is 88.32% vs 5.38% in Dec 2024

Nine Monthly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 39.20%

in Dec 2025

Figures in %

YoY Growth in nine months ended Dec 2025 has fallen from Dec 2024